Additional file 3: Figure S3. The negative control and positive control of TUNEL staining in mouse ovarian sections. Scale bar: 200 μm.

Supplemental material, sj-tif-2-tan-10.1177_17562864221147743 for Early neurological deterioration in patients with acute ischemic stroke: a prospective multicenter cohort study by Hongbing Liu, Kai Liu, Ke Zhang, Ce Zong, Hongxun Yang, Yapeng Li, Shen Li, Xin Wang, Jiawei Zhao, Zongping Xia, Bo Song, Xuming Xu and Yuan Gao in Therapeutic Advances in Neurological Disorders

Additional file 1: Supplementary Figure 1. Kaplan-Meiercurves of OS differences stratified by age, gender, tumor grade and stagebetween both groups in the entire TCGA set.

Additional file 2: Supplementary Figure 2. Partial sensitive compounds.

Additional file 2: Figure S2. The diagnostic values of 9 eRNAs for THCA patients.

Additional file 1: Figure S1. Validation of TPM1 overexpression or knockdown in BV2 cells after transfection with TPM1 plasmid or siTPM1. A mRNA level of TPM1 in BV2 cells after TPM1 plasmid transfection. Data are presented as mean ± SEM and analyzed by unpaired two-tailed Student’s t test or by one-way ANOVA with Tukey’s multiple comparison test (control plasmid vs. TPM1 plasmid, **p < 0.01). Three independent experiments were performed. B, C Western blot analysis...

Additional file 2: Figure S2. TPM1 knockdown reduces inflammation via the PKA/CREB pathway in BV2 cells. A–F qPCR analysis of TPM1, TNF-α, IL-1β, IL-6, COX-2 and iNOS in BV2 cells following treatments with LPS and siTPM1-1, siTPM1-2, or siCTR. Data are presented as mean ± SEM and analyzed by one-way ANOVA with Tukey’s multiple comparison test (compared to LPS + siCTR or control, *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.001;...

Additional file 3: Figure S3. TPM1 knockdown reduces LPS-induced inflammation and function decline in C57BL/6J mice. A, B mRNA level of TPM1 (A) and IL-10 (B) in C57BL/6 J mouse retinas after treatments with LPS and siCTR or siTPM1-1. Data are presented as mean ± SEM and analyzed by one-way ANOVA with Tukey’s multiple comparison test (compared to LPS + siCTR or LPS + siTPM1-1, *p < 0.05, **p < 0.01). n = 4 or...

Additional file 6: Figure S6. TPM1 knockdown elicits inflammation-related transcriptomic alterations in the WT retina. A, B DEGs associated with the phagosome formation pathway (A) and neuroinflammation signaling pathway (B) in WT mice after treatments with LPS and siTPM1-1 or siCTR.

Additional file 1. The effect of tucidinostat on cell proliferation, apoptosis and hepatonephric function. a Comparison of cell proliferation of 4T1, LLC, and CT26 cells treated with different doses (2.5, 5, 7.5 μM) of tucidinostat for 24 h by CCK-8 assay. b Comparison of cell apoptosis of 4T1, LLC, and CT26 cells treated with different doses of tucidinostat (2.5, 5, 7.5 μM) for 6 h by Annexin V-FITC/PI assay. c Mouse CT26 cells (5 ×...

Additional file 2. The function of tucidinostat on tumor immunity. a Functional annotation clustering of genes regulated in tumor from CT26 tumor-bearing mice on day 10 post treatment with tucidinostat (25 mg/kg, gavage, daily, n=3) or DMSO as vehicle control (DMSO, n=3). b Representative cytograms (left) or summary histograms (right) for the cell surface PD-L1 expression in CT26 cells following different doses (2.5, 5, 7.5 μM) of vorinostat, tucidinostat, and TMP-195 treatment for 24h. c...

Additional file 3. Tucidinostat plus checkpoint blockade induces improved therapeutic efficacy. a Schema of the experiment. For bioluminescence imaging (BLI) in vivo, mouse 4T1-luc (5 × 105 cells) were engrafted into the flank of BALB/c mice. When established tumors were palpable 7 days after tumor cells inoculation, mice were treated with vehicle (DMSO, n=7), tucidinostat (25 mg/kg, gavage, daily, n=7), aPD-L1 (200 μg, i.p. injection, once every 3 days, n=7), or combination (n=7). Tumors volume...

Additional file 5. Tucidinostat plus checkpoint blockade induces CCL5 secretion. a Mouse CT26 cells (5 × 105 cells) were engrafted into the flank of BALB/c mice. When established tumors were palpable 7 days after tumor cells inoculation, mice were treated with different doses (12.5, 25, 75 mg/kg, gavage, daily, n=5) of tucidinostat. The expression of CCL5 in peripheral blood serum from CT26 tumor-bearing mice on day 10 post treatment initiation. Mouse CT26 cells (5 ×...

Additional file 9: Figure S4. Cis-acting elements within the promoters of CsFLS2 and CsFLS3.

Additional file 4: Supplementary figure 4. Efficiency of miR-185-3p transfection and functional enrichment analyses of target genes of circ_0002078. (A) Efficiency verification of miR-185-3p overexpression in MEC-1 cells by qRT-PCR. (B) GO analysis results demonstrated that the target genes of circ_0002078 were enriched in positive regulation of gene expression, lymphocyte proliferation, and regulation of B cell apoptotic process. (C) KEGG pathway analysis showed that the target genes were primarily relevant to JAK-STAT signaling pathway and...

Additional file 3: Fig S2. Origin and evolution of LSSL. (A) The phylogenetic tree for the LSSL family based on the neighbor-joining (NJ) method. An NJ tree was constructed using the amino acid sequences of the LSSL proteins. All species represented by abbreviations are shown in Table S2. The bar (0.020) indicates the genetic distance. Different color lines correspond to different species groups. (B) The motif composition of the LSSL family proteins. (C) Model diagram...

Additional file 7: Fig S6. Elimination of C3 from serum to detect the deposition of LSSL and MASP-1 on the surface of HeLa cells. (A) Quantitative analysis of proteins on the HeLa cells analyzed by Alexa-488 staining followed by flow cytometry. (B, C) The histogram shows the fluorescence intensity and cell proportions of the above flow cytometry results, respectively. The data are presented as the means ± SDs. (D) Western blotting analysis of depleted and...

Additional file 2. Fig. S2: List of blood cytokines in C57BL/6J female mice treated with vehicle or 2.5, 5, or 10 mg/kg SI-2 twice a day for 7 days.

Additional file 4: Figure S3. Volcano plot showing the log2 fold change of 517 significantly differentially expressed miRNAs in CRC patients from the TCGA database.

Additional file 5: Figure S4. Prediction of 6 miRNAs (miR-29b-3p, miR-4677-3p, miR-144-3p, miR-30b-5p, miR-30e-5p and miR-374b-5p) targeting LIFR-AS1 in CRC.

Additional file 3: Fig. S3. Analysis of the methylation data from GEO database. The difference of the methylation level of H2A.Z and SFRP1 between ICC tissue and normal bile duct was visualized by box plot. (A) GSE38860. (B) GSE49656. *P<0.05, **p<0.01, ***p<0.001.

Additional file 5: Fig S4. Glycan selectivity of LSSL assessed by glycan microarrays. (A) LSSL (8 µg/mL) binding to 100 glycan microarray. The concentrations given for the glycan microarray represent those used in the carbohydrate immobilization reaction. Data are presented as the mean ± SDs; (n = 3 technical replicates). (B) Confocal microscopy detection of LSSL binding to yeast. LSSL were incubated with yeast cells (105 cells/well) in PBS for 1 h at room temperature...

Supplementary Material 3

Northeast Bioengineering Conference Poster 4/23/22

Additional File 6.